1. Home
  2. NCA vs CRDF Comparison

NCA vs CRDF Comparison

Compare NCA & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California Municipal Value Fund

NCA

Nuveen California Municipal Value Fund

HOLD

Current Price

$0.00

Market Cap

296.6M

Sector

Finance

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.58

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCA
CRDF
Founded
1987
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
296.6M
130.7M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
NCA
CRDF
Price
N/A
$1.58
Analyst Decision
Strong Buy
Analyst Count
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
N/A
543.5K
Earning Date
04-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
N/A
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
N/A
$1.48
52 Week High
N/A
$4.56

Technical Indicators

Market Signals
Indicator
NCA
CRDF
Relative Strength Index (RSI) 50.09 35.65
Support Level $9.17 $1.51
Resistance Level $9.58 $1.68
Average True Range (ATR) 0.19 0.09
MACD 0.03 -0.02
Stochastic Oscillator 57.53 7.87

Price Performance

Historical Comparison
NCA
CRDF

About NCA Nuveen California Municipal Value Fund

Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: